scholarly journals Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression

2020 ◽  
Vol 10 ◽  
Author(s):  
Junying Chen ◽  
Zeng Wang ◽  
Yuxiong Ding ◽  
Fei Huang ◽  
Weikang Huang ◽  
...  
Keyword(s):  
Immune Suppression ◽  
Suppressor Cell ◽  
Myeloid Derived Suppressor Cell ◽  
Hypofractionated Irradiation

scholarly journals Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression

Oncotarget ◽  
2015 ◽  
Vol 7 (2) ◽  
pp. 1168-1184 ◽  
Author(s):  
Laura Pinton ◽  
Samantha Solito ◽  
Vera Damuzzo ◽  
Samuela Francescato ◽  
Assunta Pozzuoli ◽  
...  
Keyword(s):  
T Cells ◽  
Immune Suppression ◽  
Suppressor Cell ◽  
Activated T Cells ◽  
Myeloid Derived Suppressor Cell

scholarly journals Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets

2021 ◽  
Author(s):  
Defne Bayik ◽  
Cynthia F. Bartels ◽  
Katreya Lovrenert ◽  
Dionysios Watson ◽  
Duo Zhang ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Tumor Microenvironment ◽  
Immune Suppression ◽  
Molecular Basis ◽  
Therapeutic Response ◽  
Myeloid Cell ◽  
Suppressor Cell ◽  
Myeloid Derived Suppressor Cell ◽  
Distinct Cell ◽  
Immunotherapy Target

Increased myeloid-derived suppressor cell (MDSC) frequency is associated with worse outcomes and poor therapeutic response in glioblastoma (GBM). Monocytic (m) MDSCs represent the predominant subset in the GBM microenvironment. However, the molecular basis of mMDSC enrichment in the tumor microenvironment compared to granulocytic (g) MDSCs has yet to be determined. Here, we report that mMDSCs and gMDSCs display differences in their tumor-accelerating ability, with mMDSCs driving tumor growth in GBM models. Epigenetic assessments indicate enhanced gene accessibility for cell adhesion programs in mMDSCs and higher cell-surface integrin expression in mouse and human mMDSCs. Integrin b1 blockage abrogated the tumor-promoting phenotype of mMDSCs and altered the immune profile in the tumor microenvironment. These findings suggest that integrin b1 expression underlies the enrichment of mMDSCs in tumors and represents a putative immunotherapy target to attenuate myeloid cell-driven immune suppression in GBM.

scholarly journals Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects

2021 ◽  
Vol 15 ◽  
pp. 117955492110355
Author(s):  
Tianhang Li ◽  
Tianyao Liu ◽  
Wenjie Zhu ◽  
Shangxun Xie ◽  
Zihan Zhao ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Escape ◽  
Suppressor Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Great Promise ◽  
Therapy Process ◽  
Myeloid Derived Suppressor Cell ◽  
Anti Cancer ◽  
Immune Suppressor

Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient selection, limited the efficacy of ICB therapy and awaited to be overcome. By timely identification and intervention of the key immune-suppressive promotors in the tumor microenvironment (TME), we may better understand the mechanisms of cancer immune-escape and use novel strategies to enhance the therapeutic effect of ICB. Myeloid-derived suppressor cell (MDSC) is recognized as a major immune suppressor in the TME. In this review, we summarized the roles MDSC played in the cancer context, focusing on its negative biologic functions in ICB therapy, discussed the strategies targeted on MDSC to optimize the diagnosis and therapy process of ICB and improve the efficacy of ICB therapy against malignancies.

Sign in / Sign up

Export Citation Format

Share Document